Introduction
The Epstein-Barr virus (EBV), which is a B lymphotropic g-herpesvirus, is widespread in the human population and is the causal agent of infectious mononucleosis. It is also associated with several malignancies, including Burkitt's lymphoma (BL), undifferentiated nasopharyngeal carcinoma, Hodgkin's lymphoma, nasal T-cell lymphoma, gastric carcinoma and B-cell lymphoma in immunocompromised individuals . EBV readily infects resting B lymphocytes in vitro and transforms them into indefinitely proliferating lymphoblastoid cell lines (LCLs). LCLs express 12 EBV gene products (termed type III latency) including 6 EBV nuclear antigens (EBNA), 3 latent membrane proteins, BamH1-A rightward transcripts (BARTs) and 2 EBV-encoded small RNAs (EBERs; Kieff and Rickinson, 2001 ). On the other hand, under type-I latency, which is also termed as BL type EBV infection, only EBNA1, BARTs and EBERs are expressed .
In all EBV-associated malignancies, EBER is the most abundant viral transcript, a nonpolyadenylated, untranslated RNA of 166 (EBER1) or 172 (EBER2) nucleotides and is highly conserved in its sequence among various EBV isolates (Rosa et al., 1981; Glickman et al., 1988; Arrand et al., 1989) . EBER forms complexes with various cellular proteins, such as RNAactivated protein kinase PKR (Clarke et al., 1991; Sharp et al., 1993) , ribosomal protein L22 (Toczyski and Steitz, 1991; Toczyski et al., 1994) , lupus erythematosisassociated antigen La and retinoic acid-inducible gene I RIG-I (Samanta et al., 2006) . In Burkitt's lymphoma cells, EBER confers resistance to IFN-a-induced apoptosis by directly binding PKR and inhibiting its phosphorylation (Nanbo et al., 2002) . The growth stimulatory properties of EBER have been demonstrated in several reports (Komano et al., 1999; Ruf et al., 2000; Yamamoto et al., 2000; Yajima et al., 2005) . Previously, we have shown that EBER induces the expression of various cellular cytokines, interleukin 10 (IL-10) in B lymphocytes (Kitagawa et al., 2000) , insulin-like growth factor 1 (IGF-1) in epithelial cells (Iwakiri et al., 2003 (Iwakiri et al., , 2005 and IL-9 in T lymphocytes (Yang et al., 2004) , each of which acts as an autocrine growth factor. However, the mechanisms by which EBER induces these cytokines have remained unresolved.
RIG-I is a cytosolic protein that detects doublestranded RNA (dsRNA) and initiates signaling to induce type I IFNs (IFN-a/b; Yoneyama et al., 2004) . Recently, we have shown that in EBV-infected BL cells, EBER is recognized by RIG-I and activates signaling to induce type I IFN (Samanta et al., 2006) . In addition to the induction of type I IFNs, activation of RIG-I signaling has been shown to induce inflammatory cytokines such as IL-6 and IL-8 (Kato et al., 2005; Wagoner et al., 2007) . Thus we considered that in BL cells, EBER-mediated RIG-I activation might also lead to the induction of other cytokines in addition to the induction of type-I IFNs. Previously, it was reported that in BL cells, PKR is not involved in IL-10 induction by EBER (Kitagawa et al., 2000) . Considering these findings, we hypothesized that in BL cells, EBER induced IL-10 through RIG-I signaling. Here, we report that in BL cells with type I latency, EBER induces IL-10 through RIG-I-mediated IRF-3 signaling.
Results

Knockdown of RIG-I results in downregulation of IL-10 expression in EBER( þ ) BL cells
To test our hypothesis that IL-10 induction in BL cells was mediated through RIG-I signaling, we transfected small interfering RNA (siRNA) targeted to RIG-I (RIG-I siRNA) into EBV( þ ) Akata cells (Akata þ ), which were derived from BL cells and maintained type-I latency (Takada et al., 1991) , and into their EBV(À) counterparts (Akata À ; Shimizu et al., 1994) . The reverse transcription (RT)-PCR results demonstrated that knockdown of RIG-I resulted in downregulation of IL-10 in Akata þ cells (Figure 1a , left panel). Estimation of IL-10 in culture supernatants by enzyme-linked immunosorbent assay (ELISA) also indicated similar results ( Figure 1a , right panel). We repeated the experiment in Mutu cells which also maintained type-I latency (Gregory et al., 1990; Nanbo et al., 2002) . The data of RT-PCR and ELISA indicated that knockdown of RIG-I resulted in downregulation of IL-10 in EBV( þ ) Mutu (Mutu þ ) cells (Figure 1b , left and right panels, respectively). These results suggested that in type-I latently EBV-infected BL cells, induction of IL-10 was dependent on RIG-I expression.
We next transfected RIG-I siRNA into EBER( þ ) EBV-infected and EBER-knockout EBV-infected Akata cells (Yajima et al., 2005) . EBER( þ ) EBV-infected Akata cells produced higher amount of IL-10 than EBER(À) EBV-infected Akata cells (Figure 1c , right panel white bars, respectively). Results obtained from RT-PCR and ELISA shown that knockdown of RIG-I resulted in downregulation of IL-10 in EBER( þ ) EBVinfected Akata cells but not in EBER(À) EBV-infected Akata cells (Figure 1c , left and right panels, respectively). Thus it was indicated that the induction of IL-10 through RIG-I was dependent on EBER expression.
To further understand that EBER induced IL-10 expression through RIG-I, we transfected RIG-I siRNA in Akata À cells stably transfected with EBER plasmid (pEKS10) or control plasmid (Komano et al., 1999 ) were transfected with RIG-I plasmid tagged with green fluorescent protein (GFP) at the C terminus or control plasmid carrying the GFP gene only. Daudi À cells were used due to their low basal expression of RIG-I and IL-10. Cell clones stably expressing GFP-tagged RIG-I (Daudi À RIG-I/GFP) or GFP (control; Daudi À GFP) were selected in media containing G418 and expression was confirmed by immunoblot analyses with anti-GFP antibody ( Figure 2a ) and anti-RIG-I antibody ( Figure 2b ). To express EBER transiently, we transfected EBER expression plasmid into RIG-I/GFP or GFP cell clones. The results of RT-PCR revealed that the transient expression of EBER led to the induction of IL-10 in RIG-I-expressing cell clones (Figure 2c ), but not in control cell clones (Figure 2d ). To further confirm our observation, we transfected purified in vitro synthesized EBER (Samanta et al., 2006) into RIG-I-expressing or control cell clones. The data obtained from RT-PCR demonstrated that EBER induced IL-10 in RIG-I-expressing cell clone (Daudi À RIG-I/GFP), but not in control cell clones (Daudi À GFP; Figure 2e ). Furthermore, it was demonstrated that only EBER1 as well as only EBER2 could induce IL-10 in RIG-I expressing cell clones (Figure 2f ).
Dominant-negative RIG-I blocks IL-10 expression in EBER-expressing BL cells
We next analysed IL-10 induction by expressing dominant-negative RIG-I plasmid in EBER( þ ) BL cells. RIG-I contains two copies of a caspase recruitment domain (CARD) at its N terminus and one helicase domain at its C terminus. It was reported that RIG-I deleted of CARD domains (C-RIG-I; Figure 3a ) functioned as a dominant-negative of RIG-I (Yoneyama et al., 2004) . We constructed a plasmid expressing dominant-negative RIG-I with the GFP gene tagged at its C terminus (C-RIG-I/GFP) and a control plasmid expressing GFP gene only, and transfected them into Mutu þ and Akata þ cells along with their EBV(À) counterparts. The expression of dominant-negative RIG-I (C-RIG-I/GFP) was confirmed by immunoblotting with an anti-GFP antibody. Results of RT-PCR analysis revealed that dominant-negative RIG-I suppressed IL-10 expression in Mutu þ and Akata þ cells (Figures 3b and c) .
To determine the role of EBER and RIG-I in the induction of IL-10, we expressed dominant-negative RIG-I plasmid or control plasmid in EBER( þ ) EBVinfected or EBER-knockout EBV-infected Akata cells. We observed that expression of dominant-negative RIG-I blocked IL-10 induction specifically in EBER( þ ) EBV-infected Akata cells but not in EBER(À) EBVinfected Akata cells (Figure 3d ). Similar results were obtained in Akata À cells stably transfected with EBER plasmid (Figure 3e ). Dominant-negative RIG-I blocks activation of IL-10 promoter in EBER-expressing cells A luciferase reporter construct driven by IL-10 promoter (À195; Heitbrock et al., 2003) was prepared. Transfection of IL-10 reporter plasmid resulted in higher luciferase expression in Mutu þ ( Figure 4a ) and Akata þ cells (Figure 4b ) than in their EBV(À) counterparts. Similarly, EBER( þ ) EBV-infected Akata cells expressed higher IL-10 promoter activity (indicated by a higher luciferase value) than EBER-knockout EBVinfected Akata cells (Figure 4c ). In agreement with this observation, Akata À cells stably transfected with EBER plasmid, which also indicated higher IL-10 promoter activity than control Akata À cells (Figure 4d ). To analyse the role of EBER and RIG-I in the activation of IL-10 promoter, IL-10 reporter plasmid was cotransfected with dominant-negative RIG-I plasmid (C-RIG-I/GFP) or control plasmid (GFP) into Mutu þ and Akata þ cells. The reporter assay demonstrated that IL-10 promoter activity was downregulated by cotransfection of dominant-negative RIG-I (C-RIG-I-GFP) plasmid (Figures 4e and f) . We next transfected dominant-negative RIG-I or control plasmid into EBER( þ ) EBV-infected and EBER(À) EBV-infected Akata cells. The results of reporter assay indicated that in presence of dominant-negative RIG-I, luciferase expression driven by IL-10 promoter was remarkably decreased in EBER( þ ) EBV-infected Akata cells, but not in EBER(À) EBV-infected Akata cells (Figure 4g) . Similarly, transfection of dominant-negative RIG-I plasmid resulted in the reduction of promoter activation in Akata À cells stably expressing EBER but not in control Akata À cells (Figure 4h) . Together, these results demonstrated that EBER activated IL-10 promoter through RIG-I.
NF-kB is not involved in RIG-I-mediated IL-10 expression by EBER Nuclear factor (NF)-kB functions downstream of the RIG-I signaling pathway (Yoneyama et al., 2004) . In response to dsRNA, NF-kB becomes phosphorylated, translocates from the cytoplasm to the nucleus, binds to promoter elements and induces the expression of several inflammatory cytokines (Kato et al., 2005; Wagoner et al., 2007) . To explore the relation between EBER and NF-kB, the basal NF-kB activity in Mutu þ and Akata (Figure 5d ). These results indicated that EBER activated NF-kB.
To examine the role of RIG-I on the activation of NF-kB, we transfected RIG-I siRNA into Mutu þ and EBER( þ ) EBV-infected Akata cells as well as Mutu À and EBER-knockout EBV-infected Akata cells. RIG-I silencing resulted in downregulation of NF-kB activity in Mutu þ ( Figure 5e ) and EBER( þ ) EBV-infected Akata cells (Figure 5f ), but not in their negative counterparts. Thus, it was confirmed that the activation of NF-kB by EBER was dependent on RIG-I expression.
To determine the role of NF-kB in IL-10 expression, we used dominant-negative IkB-a plasmid (pIkB-a; Mitchell and Sugden, 1995 Together, these results demonstrated that EBER activated NF-kB through RIG-I signaling; however, activated NF-kB did not contribute to IL-10 expression.
EBER induces IL-10 expression through IRF-3
We next investigated the role of IRF-3 which also functioned downstream of RIG-I signaling (Yoneyama et al., 2004) . The contribution of IRF-3 for the induction of IL-10 was examined after transfecting IRF-3 siRNA into Akata To further understand the role of IRF-3, we cotransfected IL-10 reporter plasmid and IRF-3 siRNA into Akata þ and EBER( þ ) EBV-infected Akata cells along with Akata À and EBER(À) EBV-infected Akata cells. We observed that in response to IRF-3 silencing, the luciferase expression regulated by IL-10 promoter was markedly reduced in Akata þ cells (Figure 6e ) and also in EBER( þ ) EBV-infected Akata cells (Figure 6f ) but not in Akata À or EBER(À) EBV-infected Akata cells. These results clearly demonstrated that EBER induced IL-10 through IRF-3 signaling.
Discussion
Activation of RIG-I signaling by dsRNA results in phosphorylation of downstream effector molecules NF-kB and IRF-3 (Yoneyama et al., 2004) . After phosphorylation, both NF-kB and IRF-3 translocate from the cytoplasm to the nucleus and bind to their cognate promoter elements to induce gene expression, which classically includes IFN-a and IFN-b (Yoneyama et al., 2004) . In addition to type-I IFNs, activation of NF-kB results in the induction of proinflammatory cytokines such as IL-6 and IL-8, which possess NF-kB binding sites in their promoter regions (Yoneyama et al., 2004; Kato et al., 2005; Wagoner et al., 2007) . Our present findings demonstrate that IRF-3 but not NF-kB is responsible for IL-10 expression. Because, silencing of IRF-3 resulted in downregulation of IL-10, whereas blocking NF-kB by dominant-negative IkB-a plasmid (pIkB-a) did not block IL-10 expression. This observation was supported by a database search demonstrating no NF-kB binding sites in human IL-10 promoter. The regulatory role of IRF-3 in the expression of chemokine, RANTES has previously been described (Lin et al., 1999) . More recently, it has been shown that in HCV infection, the expression of CXCL-8 (IL-8) is modulated by IRF-3 through RIG-I signaling (Wagoner et al., 2007) . Our present data indicate that an anti-inflammatory cytokine is induced through RIG-I-mediated IRF-3 signaling.
Previously, it was reported that in B cells, IFN-a activates human IL-10 gene (Heitbrock et al., 2003) . 
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Since EBER induces type-I IFN through RIG-I activation (Samanta et al., 2006) , the induction of IL-10 could be mediated by type-I IFN. However, the amount of interferon induced by EBER is far less than the amount required for the induction of IL-10 gene expression in BL cells (data not shown). Thus, we excluded the role of type-I IFN in EBER-mediated IL-10 induction in BL cells. Transcriptional factor Sp1 has been reported to induce IL-10 in different cell types (Tone et al., 2000) . However, in EBV( þ ) BL cells, no difference in IL-10 reporter function was observed between intact IL-10 promoter and Sp1 binding site mutated IL-10 promoter (data not shown). Hence, the contribution of Sp1 in EBER-mediated IL-10 induction seems most unlikely to occur.
LMP1 is another latent gene capable of inducing IL-10 in BL cells (Nakagomi et al., 1994) . In our experiments, we used BL-derived Mutu and Akata cells, which maintained type I latency without LMP1 expression (Gregory et al., 1990; Takada et al., 1991) . Thus, in our study, the contribution of LMP1 in the induction of IL-10 expression was excluded.
IL-10 has various biological functions. It suppresses T lymphocyte activities through downregulation of antigen presentation and direct inhibition of T-cell proliferation (de Waal Malefyt et al., 1991 , and in type-I latently infected BL cells, it functions as an autocrine growth factor (Kitagawa et al., 2000) . In EBV( þ ) BL cells, EBER induces type-I IFN through RIG-I signaling (Samanta et al., 2006) . On the other hand, EBER binds PKR, inhibits its phosphorylation (Clarke et al., 1991; Sharp et al., 1993) and thereby prevents IFN-a-mediated apoptosis (Nanbo et al., 2002) . Thus, considering various biological functions of EBER, including our present data highlighting the mechanism of IL-10 induction, we present a model of EBER functions in BL cells (Figure 7) . EBER contributes to malignant phenotype in BL cells (Komano et al., 1999) and induces several cytokines in various cell types. In EBV-infected epithelial cells, EBER induces IGF-1 (Iwakiri et al., 2003 (Iwakiri et al., , 2005 whereas in EBV-infected T cells, EBER induces IL-9 (Yang et al., 2004) . EBER is also critical in the efficient EBV-induced growth transformation of B lymphocytes (Yajima et al., 2005) . Our earlier findings with different IL-10 induction by RIG-I-mediated IRF-3 signaling M Samanta et al recombinants of EBV indicated that EBER2 encodes a transforming function in B-cells, which EBER1 does not, so that this distinct, transforming function of EBER2 likely differs from that of inducing IL-10 (Wu et al., 2007) . The mechanisms of induction of these growth-promoting cytokines by EBER in different cell types are not known. It will be interesting and valuable to investigate whether in these cells EBER can also activate RIG-I to induce those cytokines as observed in BL cells.
Materials and methods
Cells and culture
Akata cells (Takada et al., 1991) , Mutu cells (Gregory et al., 1990) and Daudi cells (Klein et al., 1968) were maintained in RPMI 1640 medium containing 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). Akata cells infected with EBER( þ ) EBV or EBER-knockout EBV (Yajima et al., 2005) , Akata À cells stably transfected with EBER plasmid or control plasmid containing neomycin-resistance gene (Komano et al., 1999) 
(c) EBER( þ )EBV-infected or EBER-knockout EBV-infected Akata cells and (d) Akata
À cells stably transfected with EBER plasmid or control plasmid. At 48 h post transfection, luciferase expression was determined using the dual luciferase reporter system (Promega), and the relative luciferase value was determined after normalizing data to the renilla internal control. The results are expressed as mean ± s.e. from three independent experiments. To assess whether EBER activated NF-kB through RIG-I, pNF-kB-luc and pCMV-luc were transfected into Mutu þ , Mutu À , EBER( þ ) EBV-infected and EBER-knockout EBV-infected Akata cells, and after 48 h, the transfected cells (0.5 Â 10 5 cells each) were reverse-transfected with 20 picomol control siRNA or RIG-I siRNA by using Lipofectamine RNAiMax (Invitrogen). After 24 h of siRNA transfection, cell lysates were analysed for relative NF-kB luciferase activity in (e) Mutu þ and Mutu À cells and in (f) EBER( þ ) EBV-infected or EBER-knockout EBVinfected Akata cells. The results are expressed as mean ± s.e. from three independent experiments. To block NF-kB activity, we transfected dominant-negative IkB-a plasmid (pIkB-a) into cells. After 48 h of transfection, total RNA was extracted and RT-PCR was carried out to analyse IL-10 expression. The efficacy of pIkB-a on NF-kB activation was verified by reporter assay at 48 h post transfection. The results are expressed as mean±s.e. from three independent experiments. Shown are results of (left panels) the reporter assay indicating the efficiency of the dominant-negative IkB-a plasmid and (right panels) the RT-PCR for IL-10 expression in (g) Mutu þ and Mutu À cells; (h) Akata þ and Akata À cells; (i) EBER( þ ) EBV-infected or EBER-knockout EBV-infected Akata cells, and (j) Akata À cells stably transfected with EBER plasmid or control plasmid.
IL-10 induction by RIG-I-mediated IRF-3 signaling M Samanta et al stably transfected with GFP-tagged RIG-I plasmid or control GFP plasmid (Samanta et al., 2006) were maintained in RPMI 1640 medium containing 600 mg ml À1 G418 (Sigma, St Louis, MO, USA).
RNA extraction and RT-PCR analysis
Total cellular RNA was extracted with TRIzol Reagent (Invitrogen) and 2 mg RNA was treated with three units of DNase I (Invitrogen) to remove genomic DNA contamination. Reverse transcription was carried out using oligo dT primer (Promega, Madison, WI, USA) and superscript II reverse transcriptase (Invitrogen), with the exception of EBER detection, for which a gene-specific 3 0 -end primer was used.
One-twentieth of the resulting cDNA was subjected to PCR using specific pairs of primers (sense and antisense, respectively): IL-10, 5 0 -CTGCTCTGTTGCCTGGTCCTCCTGA-3 To exclude the possibility of DNA contamination, control reactions were performed in parallel using samples prepared in the absence of reverse transcriptase. One-fifth of the PCR product was analysed in 2% agarose gel.
Plasmids constructs and transfections pSG5-EGFPN1 vector expressing full-length RIG-I (pSGP-EGFPN1-RIG-I) with GFP gene tagged at its C terminus and pSG5-EGFPN1 vector expressing only the C-terminal helicase domain (aa 218-925) of RIG-I (pSG5-EGFPN1-C-RIG-I) with GFP gene tagged at its C terminus were constructed as described previously (Samanta et al., 2006) . EKS10 plasmid containing 10 tandem repeats of EBER1 and EBER2 was described previously (Komano et al., 1999) . NF-kB reporter plasmid (pNF-kB/luc) encoding firefly luciferase and pCMV/ luc encoding renilla luciferase as an internal control were obtained commercially (BD Biosciences, San Jose, CA, USA). A plasmid functioning as a dominant-negative of IkB-a (pIkB-a) was a kind gift of Dr Bill Sugden (Mitchell and Sugden, 1995) .
For the IL-10 promoter luciferase reporter construct, À195 bp IL-10 promoter sequence (Heitbrock et al., 2003) from EBV(À) Daudi cells was amplified. The amplified fragment was cloned into Kpn-I/BglII restriction sites of pGL3 basic reporter vector (Promega). Plasmid DNA was prepared using Maxi-prep plasmid purification kit (Qiagen GmbH, Hilden, Germany). Plasmids were transfected by electroporation using Gene Pulser (Bio-Rad Gene Pulser II; 0.190 kV, 950 mF).
In vitro synthesis of EBER and transfection of RNA From pGEMT-EBER1 and pGEMT-EBER2 plasmids (Samanta et al., 2006) , T7 promoter-tagged (at the 5 0 end) EBER1 and EBER2 were synthesized by PCR using specific primer pairs (sense and antisense, respectively): EBER1, 5 0 -TGTAA TACGACTCACTATAGGGACCTACGCTGCCCTAGAGG TTTTGCT-3 0 and 5 0 -AAAACATGCGGACCAGC-3 0 ; EBER2, 5 0 -TGTAATACGACTCACTATAGGGACAGCCGTTGCCC TAGTGGTTTCGGA-3 0 and 5 0 -AAAACAGCGGACAAG CCGAATACC-3 0 . Using 1 mg of purified DNA (PCR product) as a template, in vitro transcription was carried out for 6 h, and transcribed RNA was purified following the manufacturer's protocol (Epicenter, Madison, WI, USA). Confirmation of in vitro-synthesized EBER1 and EBER2 were carried out, as previously described (Samanta et al., 2006) , and EBER was transfected by electroporation.
Reporter assay
To analyse basal IL-10 promoter activity, we transfected 10 mg IL-10 reporter plasmid (pGL3-IL-10P) or empty plasmid (pGL3) and 100 ng renilla internal control plasmid (pCMV-
EBVinfected or EBER-knockout EBV-infected Akata cells, and Akata
À cells stably transfected with EBER plasmid or control plasmid (5 Â 10 6 cells in each case). At 48 h post transfection, cell lysates were prepared and luciferase activity was measured using the dual luciferase reporter system following the manufacturer's protocol (Promega).
To examine the effect of dominant-negative RIG-I on IL-10 promoter activity, we cotransfected B10 mg IL-10 reporter plasmid (IL-10P) and 100 ng renilla plasmid along with 20 mg of either empty plasmid containing only GFP (pSG5-EGFPN1) or dominant-negative RIG-I plasmid (pSG5-EGFPN1-C-RIG-I) containing helicase domain of RIG-I with the GFP gene tagged at its C terminus into 5 Â 10 6 cells. After 48 h, cell lysates were analysed with dual luciferase reporter system (Promega).
To measure basal NF-kB activity, we transfected B10 mg NF-kB reporter plasmid (pNF-kB/luc) encoding firefly luciferase gene and B100 ng renilla plasmid (pCMV-luc) as an internal control into 5 Â 10 6 cells. To analyse the function of dominant-negative IkB-a plasmid, we cotransfected 10 mg pNF-kB/luc and 100 ng renilla plasmid (pCMV-luc) along with 20 mg dominant-negative IkB-a plasmid (pIkB-a) or control plasmid (pCMV) into 5 Â 10 6 cells. At 48 h post transfection, reporter assay was carried out using dual luciferase reporter system (Promega).
Activation of IL-10 promoter by IRF-3 was determined by cotransfecting 100 nmol control siRNA or IRF3 siRNAs and 10 mg IL-10 promoter reporter plasmid along with 100 ng renilla plasmid as an internal control into 5 Â 10 6 cells. Results were recorded at 48 h post siRNA treatment, and the relative luciferase activity was determined using the dual luciferase reporter system (Promega).
Immunoblot analysis
Whole cell lysates were prepared from 3 Â 10 6 cells in 100 ml of lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4, 0.1 mg ml À1 leupeptin, 1 mM PMSF and phosphatase inhibitor cocktail (I and II, Sigma; 1% v/v) . Quantification of proteins in cell lysates was carried out using Bio-Rad protein assay kit. Cell lysates containing B30 mg of protein were heat-denatured, resolved by 8% SDS-polyacrylamide gel electrophoresis, and electrotransferred to nitrocellulose membrane. Membranes were blocked in Tris-buffered saline containing 5% nonfat milk and 0.05% Tween 20 and incubated overnight at 4 1C with primary antibodies: anti-RIG-I , anti-GFP (BD Biosciences) and anti-b-actin antibodies (Sigma), followed by reaction with HRP-conjugated anti-rabbit immunoglobulin G (IgG)-antibody (1:2000) or anti-mouse IgGantibody (1:5000; GE Healthcare, Buckinghamshire, UK). 
RNA interference
To knockdown RIG-I, we transfected 100 nmol of siRNA containing dsRNA duplexes (Invitrogen) composed of 25 nucleotides of sense 5 0 -UUAGGAUUCUCAUUGCUGG GAUCCC-3 0 and antisense 5 0 -GGGAUCCCAGCAAUGA GAAUCCUAA-3 0 into 2 Â 10 5 cells. For IRF-3 knockdown, we transfected 100 nmol of dsRNA duplexes targeting IRF-3, a mixture containing three IRF-3 siRNAs: IRF-3 siRNA(1), sense 5 0 -UAAACGCAACCCUUCUUUGCGGUUG-3 0 and antisense 5 0 -CAACCGCAAAGAAGGGUUGCGUUUA-3 0 ; IRF-3 siRNA(2), sense 5 0 -AUCAGAAGUACUGCCUC CACCAUUG-3 0 and antisense 5 0 -CAAUGGUGGAGGCA GUACUUCUGAU-3 0 and IRF-3 siRNA(3), sense 5 0 -AACU CAUCCAGAAUGUCUUCCUGGG-3 0 and antisense 5 0 -CC CAGGAAGACAUUCUGGAUGAGUU-3 0 . To eliminate nonspecific effects of siRNA, Stealth RNAi Negative Control Duplex Medium GC (48%; Invitrogen) was transfected simultaneously. Lipofectamine RNAiMax (Invitrogen) was used for reverse transfection of cells following the manufacturer's protocol (Invitrogen). At 48 h post siRNA transfection, total RNA was extracted and RT-PCR was carried out to analyse the silencing effect of siRNA.
ELISA
We transfected 100 nmol of RIG-I siRNA, IRF-3 siRNA and control siRNA (Invitrogen) into EBV( þ ) and EBV(À) Mutu and Akata cells; EBER( þ ) EBV-infected or EBER-knockout EBV-infected Akata cells; Akata À cells stably transfected with EBER plasmid or control plasmid (2 Â 10 5 cells each). We used Lipofectamine RNAiMaX (Invitrogen) to transfect these siRNAs following reverse-transfection protocol (Invitrogen). At 72 h post siRNA transfection, we collected the culture supernatants and performed ELISA using an ultra sensitive hIL-10 kit (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol, and the value (picogram per milliliter) was normalized to 2 Â 10 5 cells.
